As optimal function is critical to an individual’s health, safety, and privacy, the risk of security threats targeting an artificial pancreas is of paramount concern and has not been sufficiently considered in the research and development of these emerging medical devices, according to a Perspective article published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until June 12, 2015.
Yogish C. Kudva, MD and coauthors from Mayo Clinic (Rochester, MN) and University of Virginia (Charlottesville) reviewed the recent studies conducted on artificial pancreas systems and identify security vulnerabilities related to both internal and external factors that could put users at risk. These include software integrity and the risk of malware such viruses, worms, or spyware, access to personal information, or device manipulation. External concerns may include exposure to electromagnetic fields that could interfere with proper function of the system.
In the article “Cybersecurity in Artificial Pancreas Experiments,” the authors propose the need for a more formal and consistent approach in reporting the technical characteristics and performance of an artificial pancreas during experimental studies. This would encompass the various components of these complex systems, which typically include a continuous glucose monitor, fingerstick blood glucose device, and insulin pump.
“As the technology keeps advancing, we have to be vigilant about interference with medical devices, especially those that automatically control insulin infusion in the artificial pancreas. Kudva et al. bring out many challenges one faces while making sure the upcoming devices are safe,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.